S
epsis is a clinical syndrome that arises from an inappropriate and excessive systemic inflammatory response against infection (1) . With adequate fluid resuscitation and pharmacologic interventions, systemic hemodynamics of sepsis is characterized by a hyperdynamic circulatory state, resulting in augmentation of oxygen supply to tissues. The importance of sufficient tissue oxygenation was recently addressed in a large-scale clinical trial in which patients at the early stage of sepsis were treated by aggressive management to optimize hemodynamic function (2) . During the progression of sepsis, however, regional tissue dysoxia becomes evident and organ dysfunction including heart dysfunction develops (3) . Several mechanisms are considered to be responsible for myocardial dysfunction in sepsis (4, 5) . For example, proinflammatory cytokines like tumor necrosis factor (TNF)-␣ have been shown to play a consequential role in the pathogenesis of myocardial dysfunction in sepsis (6, 7) . In addition, the number of ␤-adrenergic receptors was reduced in critically ill patients involving sepsis (8) . Few specific strategies, however, have been demonstrated to restore myocardial dysfunction effectively in sepsis.
There is increasing evidence that ␤-blocker therapy during perioperative periods improves morbidity and mortality in high-risk patients with ischemic heart disease (9) . Another study showed a tenfold decrease in the 30-day perioperative incidence of death from cardiac causes and nonfatal myocardial infarction in ␤-blocker-treated patients undergoing vascular surgery (10) . Such protective effects of ␤-blocker for ischemic myocardium could be accounted for by an improved balance between oxygen supply and consumption (11) , regulation of cytokine release (12, 13) , and/or restoration of down-regulated ␤-receptor (14) . A question remains, however, whether ␤-blocker therapy would improve myocardial dysfunction at a hyperdynamic stage of sepsis where cardiac work is augmented. We therefore designed the present study to examine if infusion of esmolol, a ␤1-selective adrenergic blocker, suppressed the progression of myocardial dysfunction in a normotensive, hyperdynamic model of septic rats.
METHODS
This study protocol was approved by the animal care and use committee of Keio University School of Medicine.
Animal Preparation. Thirty-one male Wistar rats, weighing 320 -360 g, were studied after 3-to 7-day acclimatization periods in our laboratory. With sevoflurane anesthesia in oxygen, the jugular vein and carotid artery were cannulated with a catheter (PE50; Intermedic, Sparks, MD) under sterile conditions. Then a laparotomy was performed and a ligature was placed around the cecum immediately distal to the ileocecal valve. The cecum was then punctured twice with an 18-gauge needle. Fol-lowing this preparatory surgery, normal saline was infused at 2 mL/hr via the catheter for the next 24 hrs. Rats were allowed to move freely in cages and have water and laboratory chow ad libitum. This preparation was demonstrated to produce normotensive, hyperdynamic sepsis without apparent tissue hypoxia as previously described (15, 16) . In addition, to determine ex vivo myocardial function of normal rats in our experimental setting, we studied seven sham rats, which received the same catheterization without cecal ligation and perforation (CLP), under the same study protocol described next.
Study Protocol. After the preparatory surgery, the animals were randomized into three groups: Group C (n ϭ 11) received normal saline, group E-10 (n ϭ 10) received esmolol infusion at 10 mg/kg/hr, and group E-20 (n ϭ 10) received esmolol infusion at 20 mg/kg/hr for the next 24 hrs. Our pilot study using a P-U conductance system (ARIA-1, Millar, Houston, TX) demonstrated that esmolol at the rate of 20 mg/kg/hr reduced cardiac output to an approximately 20% lower level compared with the baseline in normal rats under general anesthesia and 10 mg/kg/hr did not significantly influence cardiac output values. At 1 and 24 hrs after randomization, blood samples were taken via the arterial catheter for measurements of white blood cell count, lactate, and proinflammatory cytokines. Twenty-four hours after randomization, animals were reanesthetized with sevoflurane in oxygen. After the intravenous injection of heparin (3000 IU/ kg), the hearts of animals were rapidly excised, mounted on a nonrecirculating Langendorff apparatus to allow further preparation, and perfused with modified Krebs-Henseleit solution at 37°C (composition in mM: NaCl 120, KCl 4.8, KH 2 PO 4 1.2, MgSO 4 1.2, CaCl 2 1.25, NaHCO 3 25, and glucose 11) as described previously (17) . The perfusion buffer was equilibrated with a 95% oxygen/5% CO 2 gas mixture, resulting in a buffer PO 2 Ͼ400 mm Hg.
Spontaneous beating heart was used throughout the isolated-perfusion study periods. Following the placement of an aortic cannula, the left atrium was cannulated through the pulmonary vein to allow filling and contraction of the left atrium. With the left atrial cannula open, the Langendorff column was closed and the aortic outflow line opened so that buffer entering through the left atrium could be pumped out of the left ventricle (i.e., the antegrade working mode). Since perfusion of the left atrium provided sufficient heart rate, electrical pacing was obviated to examine left ventricular function in this experiment. During this working mode, a mean aortic pressure of 70 cm H 2 O was maintained by a column height equivalent to 70 cm H 2 O. Following the ligation of superior and inferior vena cava as well as pulmonary veins to ensure that the coronary effluent passed through the pulmonary artery, the pulmonary artery was cannulated with a 16-gauge steel cannula, and right ventricular outflow was monitored with transit-time ultrasound flowmeter (T206, Transonic Systems, NY) for the measurement of coronary flow. The probe of this flowmeter was also attached to the aortic flow root. Simultaneously, a catheter-tip pressure transducer (postcraniotomy subdural pressure monitoring kit, 110-4G, Neuro Care Group, Camino, CA) was inserted into left ventricle through the left atrium.
After initial 10 mins of perfusion in the working heart model, baseline measurement at 10 cm H 2 O preload, by adjusting the height of the left atrial buffer reservoir above the heart, was performed and repeated at various preloads increasing every 2 cm H 2 O up to 20 cm H 2 O after 15 mins of stabilization.
Specific Measurements and Calculations. Cardiac output (CO) was defined as the sum of coronary and aortic flows in this experimental setting. Left ventricular pressure was continuously monitored with a transducer (postcraniotomy subdural pressure monitoring kit, 110-4G, Neuro Care Group, Camino, CA, and Life Scope II, Nihon Koden, Tokyo) and recorded in a digital recorder (PC208, Sony, Tokyo). Using computer software (Acqknowledge version 3.0 data acquisition systems, Biopac Systems, Goleta, CA, and Microsoft Excel, Microsoft, Redmond, A), left ventricular peak systolic pressure, left ventricular enddiastolic pressure, maximum rate of left ventricular pressure increase (dP/dt max ), minimum rate of left ventricular pressure increase (dP/dt min ), and heart rate were calculated, based on the averages of five beats. Left ventricular developed pressure, which was regarded as a marker of contractility of the isolated rat heart, was calculated by subtracting left ventricular end-diastolic pressure from left ventricular peak systolic pressure.
The PO 2 of the perfusion medium obtained at preperfusion (inflow) and right ventricular outflow (outflow) was determined by using a standard blood gas analyzer (ABL 700 series, Radiometer Trading, Copenhagen). Oxygen delivery was calculated as inflow oxygen tension, in millimeters of mercury, multiplied by oxygen solubility (24 L/mL Krebs-Ringer's solution at 760 mm Hg·oxygen and 37°C) and coronary flow (in milliliters per minute). Myocardial oxygen consumption was calculated as oxygen solubility multiplied by the difference between inflow and outflow oxygen tension times coronary flow. Cardiac efficiency was determined as the ratio of cardiac work, the product of cardiac output (mL/min) ϫ left ventricular peak systolic pressure (mm Hg), to myocardial oxygen consumption, as described previously (18) .
Biochemical Analyses. The arterial blood samples at 1 and 24 hrs were used to determine white blood cell counts by an analyzer (Celltac, Nihon Kohden, Tokyo, Japan) and lactate by a standard blood gas analyzer (ABL 700 series, Radiometer Trading, Copenhagen). Residual blood was centrifuged at 2500 rpm for 10 mins at 4°C and then stored at Ϫ80°C for measurements of cytokines. TNF-␣ and interleukin-1␤ were measured in duplicate by enzyme-linked immunosorbent assays using commercially available antibodies (Immunoassay Kit, Biosource International, CA). Briefly, after incubation in the immobilized antibody and a biotinylated antibody specific for each cytokine, streptavidine-peroxidase is added. This binds to the biotinylated antibody to complete the four-member sandwich. Then, a substrate solution is added, which is acted on by the bound enzyme to produce color. The intensity of this colored product is directly proportional to the concentration of each cytokine. The intensity was measured using a plate analyzer (enzyme-linked immunosorbent assay ETY-3A, Toyosokki, Tokyo, Japan).
Immunohistochemical Quantification of Myocardial ␤1-Receptor. In a separate series of experiments, density of myocardial ␤1-receptor was determined by immunohistochemistry. In addition to three sham rats, three rats in each group were examined. At 24 hrs after CLP, the rats in three groups were reanesthetized and the hearts were immediately excised and freeze-clamped between blocks of metal cooled in liquid nitrogen and stored at Ϫ80°C until the analyses. The ␤1-adrenergic receptor was analyzed using antihuman ␤1-adrenergic receptor rabbit polyclonal antibody (PA1-049), which detects ␤1-adrenergic receptor from mouse and rat tissues. Briefly, sections of hearts were prepared from each of two randomly chosen blocks per tissue per animal and were fixed in dimethyl ketone at 4°C for 20 mins. Then these sections were immersed in 0.3% hydrogen peroxide in methanol for 5 mins to block endogenous peroxidase activity, followed by three rinses in phosphate buffered saline. Sections were incubated with antihuman ␤1-adrenergic receptor rabbit polyclonal antibody (PA1-049) at a dilution of 1:200 at 4°C overnight. After three rinses in phosphate buffered saline, sections were incubated for 10 mins with secondary antibody: biotin-conjugated mouse and rabbit antigoat immunoglobulin, followed by peroxidase-conjugated streptoavidin. After three rinses in phosphate buffered saline, positive staining was visualized using 3,3'-diaminobenzidine tetrahydrochloride. Slides were then counterstained with hematoxyline. Ten images per each sample were randomly photographed using a microscope attached modular photomicrographic system (Nikon Eclipse TS 100, Nikon, Tokyo). The immunostaining area of the myocardium was measured using a computer software (NIH image 1.63 software, NIH, Bethesda, MD) in a blinded manner, and the ratio of this area to all field of the image was determined as the density of ␤1-receptors.
Statistical Analysis. Values were described as mean Ϯ SD unless otherwise specified. To compare and contrast the effects of esmolol across the groups during working heart preparation, two-way analysis of variance was employed using the statistical package SPSS/ 10.0J for Windows (SPSS, Chicago, IL). Where appropriate, directed pairwise comparisons of individual groups were conducted using a Bonferroni-corrected 95% confidence interval. Since the sham rats were not randomized with other animals, statistical analyses vs. the septic rats were not applied. The data of sham rats are presented in the results as the standard of hemodynamic changes and myocardial function in our experimental setting. For analysis of ␤1-adrenergic receptor density, one-way analysis of variance was employed. Directed comparisons of individual groups were conducted using Scheffé's test. We considered p Ͻ .05 as significant.
RESULTS
All CLP rats demonstrated a reduction of activity, pilo-excretion, and exudation around eyes and nose at 24 hrs after operation. At postmortem, panperitonitis with moderate volume of ascites was confirmed in all CLP rats.
In Vivo Hemodynamic Changes in Sham and CLP-Induced Septic Rats. Table 1 shows the changes of heart rate and mean arterial pressure for 24 hrs in sham and CLP-treated rats with or without esmolol infusion. In the control group, heart rate at 24 hrs increased significantly compared with 0 hr (p Ͻ .05), whereas mean arterial pressure remained constant during the 24-hr periods. At 24 hrs, heart rates in both esmolol groups, which appeared to be comparable with the sham group, were significantly lower than those in the control group (p Ͻ .05). Mean arterial pressure at 24 hrs in both esmolol groups was significantly reduced compared with 0 hr (p Ͻ .05), but only the E-10 group showed a significant difference vs. the control group. In the sham group, both variables remained constant throughout the study periods. As shown in Figure 1 , white blood cell counts, which were comparable at 1 hr between the three groups, were significantly reduced to a similar extent at 24 hrs (p Ͻ .05). Arterial lactate levels were not significantly different and ranged within normal limits at both 1 and 24 hrs in all study groups.
Ex Vivo Myocardial Function in Sham and CLP-Induced Septic Rats. Table 2 illustrates the changes of heart rate, stroke volume, and myocardial function at various levels of preload, ranging between 10 and 20 cm H 2 O, in a working heart preparation. Heart rate was not significantly different in all three groups, whereas stroke volumes in both esmolol groups were significantly higher almost throughout the study periods vs. the control group. In the sham group, heart rate showed an increasing trend with the elevation of preload, whereas stroke volume remained constant throughout the study periods. CO in both esmolol groups was approximately twice as high as that in the control group (p Ͻ .05) at all preload levels. In particular, the changes of CO in the E-20 group were almost identical to those of the sham group. The variables to reflect left ventricular contractility or dilation such as left ventricular developed pressure, dP/dt max , and dP/dt min in both esmolol groups were basically maintained higher than those in the control group (p Ͻ .05), whereas statistical significance was not achieved at some preload periods. There were no significant differences between two esmolol groups in these variables such as left ventricular developed pressure, dP/dt max , and dP/dt min . All these variables in the sham group were slightly higher than those in esmolol-treated groups throughout the study periods. The myocardial oxygen consumption in the E-20 group, which was comparable with the sham group, was significantly higher vs. the control group (p Ͻ .05), whereas the E-10 group, which ranged between the values of the control and E-20 groups, did not show a significant difference. Figure 2 shows the changes of cardiac work and cardiac efficiency at various lev- els of preload, ranging between 10 and 20 cm H 2 O, in working heart preparation. In two esmolol-treated groups, both cardiac work and cardiac efficiency were significantly higher than in the control group throughout the study period (p Ͻ .05), indicating that esmolol infusion preserved cardiac work more efficiently (i.e., more efficient oxygen utilization to a certain extent of cardiac work) in septic rats. In addition, the rightward and upward shift of the peak values in the esmololtreated rats suggests that the FrankStarling curve in septic myocardium is improved by esmolol infusion. The values at various preloads in the E-20 group were similar to the sham group.
Esmolol and Proinflammatory Cytokines in Septic Rats. Figure 3 illustrates the changes of TNF-␣ and interleukin-1␤ at 1-and 24-hr periods in all CLP groups. In the control group, TNF-␣ showed an increasing, but not significant, trend at 24 hrs vs. 1 hr, whereas esmolol infusion at either dose caused a significant reduction of TNF-␣ at 24 hrs compared with the control group (p Ͻ .05). Interleukin-1␤ level in plasma did not change significantly in all study groups. Figure 4 illustrates the representative microscopic images of positive immunostaining ␤1-adrenergic receptor in myocardium from sham rat and three groups. Less immunostaining for ␤1-adrenergic receptor was observed in the control group compared with sham rat as shown in Figure  4A and 4B. In contrast, with esmolol infusion at either dose, ␤1-receptor expression on myocardium was much higher than in the control group (Fig. 4C and  4D ). Figure 5 shows the density of ␤1-adrenergic receptors. The ratio of positive immunostaining area to whole area in the control group was significantly reduced to approximately the 60% level of the sham rat (p Ͻ0.05). Those ratios in the esmolol-treated septic rats ranged between the sham and control groups, but no statistical difference was found vs. the sham group.
Esmolol and ␤1-Adrenergic Receptor Density in Septic Myocardium.

DISCUSSION
Although augmenting systemic oxygen delivery to match oxygen needs was considered the basic concept for the treatment of sepsis (19) , clinical trials demonstrated that hemodynamic therapy aimed at achieving supranormal values of CO did not necessarily improve the outcome in critically ill patients (20, 21) . A new guideline clearly documented that a strategy of increasing CO to accomplish a predefined elevated level was not recommended (22) . Despite no evidence of a global deficit of oxygen supply (23) , septic hearts per se are recognized as relatively ischemic due to disturbed microcirculation and mitochondrial dysfunction (24 -26) . We therefore wondered whether augmentation of CO in hyperdynamic sepsis, requiring further cardiac work, became another circumstance to deteriorate its function and subsequently did not improve the outcome in septic patients. The present study demonstrated that, in a peritonitis-induced septic rat, continuous infusion of esmolol preserved myocardial function without evidence of deteriorating tissue hypoxia. Simultaneously, this study suggested that such cardioprotective effects of esmolol were caused by improved myocardial oxygen utilization, possibly based on the blockade of persistent ␤-adrenergic stimulation, the reduc- tion of TNF-␣ discharges, and the restoration of suppressed ␤1-adrenergic receptor density in myocardium during the progression of sepsis. In this model, systemic inflammatory responses to infection are obvious, reflected by a marked reduction of white blood cell counts and a significant elevation of heart rate at 24 hrs. With adequate fluid resuscitation, it has been appreciated as most clinically relevant to a hyperdynamic sepsis, concomitantly obviating the confounding factors like hypotension or significant tissue hypoxia (15, 16) . Under these conditions, however, cardiac performance in septic rats was significantly depressed in the ex vivo study, demonstrating that CO in the control group was reduced to approximately 50% level vs. the sham rats when the preload and afterload were kept identical ( Table 2) . On the contrary, all variables of myocardial function such as left ventricular developed pressure, dP/dt, and CO were significantly improved by continuous infusion of esmolol (Table 2) , accompanied by augmented cardiac work and cardiac efficiency (Fig. 2) , indicating that esmolol infusion during the development of sepsis improved myocardial oxygen utilization and contractility. Interestingly, heart rate remained constant and stroke volume was kept higher in the esmolol-infused rats. Accordingly, ␤-blocker not only may augment myocardial contractility but also may increase end-diastolic volume of septic heart by improving its diastolic function. Previous clinical study demonstrated that the survivors from septic shock had an acutely dilated left ventricle with an increased end-diastolic volume for the first few days, whereas nonsurvivors showed normal values throughout the course of their illness until death (27, 28) . Infusion of ␤-blocker could induce such alterations of septic myocardium to enlarge its enddiastolic volume, subsequently protecting the host.
Application of ␤-blocker has been demonstrated to improve acute and longterm prognosis in ischemic heart disease and to reduce perioperative incidence of death from cardiac causes in high-risk patients (9, 10) . Although the present study did not clarify whether such beneficial effects of ␤-blocker improved the outcome in septic hosts, ␤-blocker infusion restored the function of septic myocardium up to the level of sham rats. Several possibilities to account for this promising property of ␤-blocker in septic myocardium have been proposed. First, significant reduction of heart rate induces the improvement of oxygen balance and the prolongation of diastolic phase, subsequently providing an antiischemic effect on the myocardium (11) . Such effects of ␤-blocker could contribute to protection of septic hearts. Second, prolonged and intensive ␤-adrenergic receptors stimulation leads to desensitization and down-regulation of ␤-adrenergic receptors, which seriously impairs cardiac function (11) . Since sepsis is accompanied by a massive discharge of endogenous catecholamines (29) , infusion of ␤-blocker during the development of sepsis may be able to block this pathway of desensitization. Third, attenuation of adrenergic nervous system by ␤-adrenergic blockade contributes to the suppression of TNF-␣ and the preservation of cardiac function (6, 30) , because TNF-␣ and interleukin-1␤ have been shown to synergistically depress myocardial contractility by disrupting the transmembrane ␤-adrenergic signal transduction (12, 13) . Owing to a limited amount of blood sampling in rat, we did not measure these cytokines at the other time period when their discharges might be maximized during 24 hrs after CLP. These effects of ␤-adrenergic blocker to suppress the discharges of cytokines like TNF-␣ could be the major mechanism for preservation of myocardial function in sepsis. In addition, recent study supported that TNF-␣ secreted from myocytes, which produced no measurable rise in plasma, developed myocardial dysfunction after ischemiareperfusion, shock, or endotoxemia (30 -33) . The myocardium produces as much TNF-␣ per gram of tissue in response to endotoxin as either the liver or spleen, both of which include large macrophage populations, the major source of TNF-␣ (33). Although we did not assess the expression of TNF messenger RNA on the myocardium or the effects of TNF-␣ converting enzyme inhibitor (34) , in the present study, ␤-blocker infusion might minimize these responses and preserve greater myocardial function as observed in patients with heart failure (35, 36) . Finally, although the measurement of receptor density in this study did not allow us to evaluate the accurate number or Figure 2 . Changes of cardiac work and cardiac efficiency in an isolated working heart between the groups at different preloads. Cardiac efficiency ϭ the ratio of cardiac work, the product of cardiac output ϫ left ventricle peak systolic pressure, to myocardial oxygen consumption. Significant difference was found between the groups through all preloads (*p Ͻ .05). function of ␤1-adrenergic receptor, the restoration of receptor density might protect myocardial function. In patients with septic shock, an approximately 40% reduction of the ␤-adrenergic receptor density was demonstrated (8) , indicating that the potency of ␤-adrenergic stimulation in septic myocardium was reduced at the level of receptors. In the present study, we found comparable results of ␤-receptor down-regulation in septic myocardium but failed to show the significant restoration of receptor density with esmolol infusion vs. the control group. Although others demonstrated that ␤-adrenergic receptors in myocardium were initially externalized during hyperdynamic phase but were internalized during the late stage of sepsis (37) , further study is needed to elucidate the changes of ␤-adrenergic receptor density in septic myocardium.
There are several issues to interpret the data herein. Compared with in vivo analyses, an isolated working heart preparation eliminates the impacts of circulating endogenous humoral mediators and inflammatory cells. If these components, which are able to modulate sepsisrelated myocardial dysfunction, persist during the evaluation periods, the protective effects of esmolol might not become apparent. To this point, however, it should be noted that esmolol per se was excluded from the perfusion medium. Additionally, the dose of esmolol infusion was determined in healthy, but not septic, rats under general anesthesia in our pilot study. In other words, infusion of esmolol at 20 mg/kg/hr, which could reduce CO to an approximately 80% level in healthy rats, might possess more profound cardiodepressive effects on septic hearts in vivo. Although the dose of esmolol should be reduced in a disease condition like sepsis, the half dose in this study showed a similar protective property on myocardial function during the development of sepsis. Some may argue that arterial lactate is a reliable marker to reflect the progression of anaerobic tissue metabolism in sepsis (38) . Several other mechanisms such as dysfunction of pyruvate dehydrogenase, delayed lactate clearance, or epinephrine-stimulated aerobic glycolysis could contribute to an eleva- 
